"10.1371_journal.pone.0074345","plos one","2013-09-12T00:00:00Z","Lucia Cuppini; Angelica Calleri; Maria Grazia Bruzzone; Elena Prodi; Elena Anghileri; Serena Pellegatta; Patrizia Mancuso; Paola Porrati; Anna Luisa Di Stefano; Mauro Ceroni; Francesco Bertolini; Gaetano Finocchiaro; Marica Eoli","Department of Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico C, Besta, Milan, Italy; Department of Hematology-Oncology, European Institute of Oncology, Milan, Italy; Department of Neuro-Radiology, Fondazione IRCCS Istituto Neurologico C, Besta, Milan, Italy; Department of Neurology, Fondazione IRCCS Istituto Neurologico Nazionale C. Mondino, Pavia, Italy","Conceived and designed the experiments: LC FB GF ME. Performed the experiments: AC EP EA ALDS SP PP. Analyzed the data: LC MGB SP PM MC FB GF ME. Contributed reagents/materials/analysis tools: AC EP EA PP. Wrote the manuscript: LC FB GF ME.","Bevacizumab and irintecan were supplied by Roche S.p.A. (Monza, Italy) and Hospira S.r.l. (Napoli, Italy), respectively. There are no further patents, products in development or marketed products to declare.  This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","09","Lucia Cuppini","LC",13,TRUE,4,6,8,4,TRUE,TRUE,FALSE,0,NA,FALSE
